Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity of Fluzone Influenza Virus Vaccine (2006-2007 Formulation).
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2014
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 12 May 2009 Official Title amended as reported by ClinicalTrials.gov.
- 01 Apr 2009 Primary endpoint identified as geometric mean antibody titre as reported by ClinicalTrials.gov.
- 24 Sep 2008 Primary outcomes identified as safety and immunogenicity of Fluzone vaccine as reported by ClinicalTrials.gov.